M Bio Thechnology is a world leading company focused on the discovery and development of innovative therapeutic strategy for Mycoplasma Infectous Diseases (MID). M Bio Technology develops innovative vaccine, diagnostics, precision therapy for MID.
MID is a cause of pneumonia, asthma, COPD, Interstitial pneumonia, fibrosis and other various autoimmune diseases (SjS:Stevens-Johnson syndrome), Kawasaki disease, SHP:IgA nephritis, RA:rheumatoid arthritis) and neurological diseases (Epilepsy, CIDP:chronic inflammatory degenerative polyneuropathy, Parkinson's disease, GBS, CFS/FM), also stroke.
The pathogenesis of Mycoplasma Infectious Diseases (MID) is systemic vasculitis/neuritis, which had been made it extremely difficult to diagnose and treat (MID SpectrumTM). M Bio Technology Inc. develops innovative vaccine (MID VaccineTM), diagnostics (MID PrismTM), precision therapy (MID Precision MedicineTM) for Mycoplasma Infectious Diseases (MID).
Animal POC shows safty and efficacy. MID Vaccne is expected as usedful for both prophylactic and therapeutic, including vaccines for MIDs, as well as monoclonal antibodies against infectious agents.
M Bio Thechnology has acquired international patents for the diagnosis, prevention, and precision treatment of MIDs, which include not only pneumonia and asthma but also intractable neurological, skin, and renal diseases, in which common pathological mechanism is inflammation/fibrosis around blood vessel and nerves throughout the entire body caused by MIDs.